TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma

TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma

We examined the efficacy of selective inhibition of cyclin-dependent kinase 5 (CDK5) in glioblastoma by TP5. We analyzed its impact in vitro on CDK5 expression and activity, cell survival, apoptosis and cell cycle. DNA damage was analyzed using the expression of γH2A.X and phosphorylated ATM. Its to...

Full description

Bibliographic Details
Main Authors: Emeline Tabouret, Herui Wang, Niranjana Amin, Jinkyu Jung, Romain Appay, Jing Cui, Qi Song, Antonio Cardone, Deric M. Park, Mark R. Gilbert, Harish Pant, Zhengping Zhuang
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
glioblastoma
CDK5
radiotherapy
chemotherapy
ATM
DNA damage
Online Access:https://www.mdpi.com/2072-6694/12/7/1935

Internet

https://www.mdpi.com/2072-6694/12/7/1935

Similar Items